These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|---|---|---|
Dr. Xing has served as Executive Chair of the Board of Directors of Mundipharma China since 2022. Mundipharma is a multinational pharmaceutical leader. From 2019 to 2022, Dr. Xing held the position of Global Senior Vice President, President of Greater China for Envista Holdings Corporation (a dental equipment and supplies company). Prior to that, Dr. Xing served in numerous leadership roles at Eli Lilly and Company (a global pharmaceutical company), including Senior Director, Global New Product Planning and Payer Marketing, Pricing, Reimbursement and Access of Lilly Diabetes from 2018 to 2019, Senior Director, Global Payer Marketing, Pricing, Reimbursement and Access of Lilly Diabetes from 2015 to 2018, Vice President of Lilly China Oncology from 2012 to 2014 and Vice President of Corporate and Government Affairs and Market Access from 2010 to 2012, while based in Shanghai. Prior to Eli Lilly, from 2007 to 2010 Dr. Xing was Vice President and General Manager of Asia Pacific and Japan Operations at Panomics and Affymetrix, which was acquired by Thermo Fisher Scientific. Dr. Xing was General Manager and China President of Illumina (a global next generation gene sequencer company) from 2005 to 2007. Dr. Xing has served as a Board advisor of Lee Kum Kee Group (privately-held global manufacturer of sauces and condiments), since February 2025. Dr. Xing also served as Board advisor to the Board of Directors of Mars, Incorporated (a global manufacturer of confectionery, pet food and provider of animal care services) from 2019 to 2024. Dr. Xing has a PhD in biology from the Hong Kong University of Science and Technology. | |||
Mr. Wunderlich has served as the President and CEO of Huhtamaki Oyj (a Nasdaq Helsinki-listed global food packaging company) since January 2025. Prior to this role, he was an independent consultant and a senior advisor to private equity firms. He is currently the Chair of the Board of Directors of Shepherd Building Group Ltd. (a privately held U.K. construction company). Until January 2025, Mr. Wunderlich served as a director of Huhtamaki Oyj, Essentra PLC (an LSE-listed manufacturer and distributor of essential industrial components) and Klöckner Pentaplast (a privately held international manufacturer of plastic packaging products for the pharma, healthcare and food industries headquartered in Luxembourg). He is a former member of Amcor Limited’s Global Executive Team and former President of the business group Amcor Flexibles Asia Pacific (packaging solutions including healthcare and pharma packaging). Mr. Wunderlich also formerly served as a director of LINPAC Group and AMVIG Group. | |||
Mr. Trerotola has served as the Chief Executive Officer for Enovis Corporation since April 2022 and as President and Chief Executive Officer of its predecessor Colfax Corporation from July 2015 to April 2022. He has served as Chair of the board of directors of Enovis since May 2023. Enovis is an innovation-driven medical technology company formed when Colfax separated from its industrial businesses and was renamed. Prior to joining Enovis, from 2014 to 2015, Mr. Trerotola was an Executive Vice President and a member of the Office of the Chief Executive at DuPont de Nemours, Inc. (a global innovation leader with technology-based materials and solutions) and from 2013 to 2014 he served as Senior Vice President. While at DuPont, he was responsible for DuPont’s Electronics & Communications and Safety & Protection segments (2014), and he also had corporate responsibility for DuPont’s Asia-Pacific business. Prior to joining DuPont in 2013, Mr. Trerotola served in leadership roles at Danaher Corporation (a global science and technology innovator), since 2007, and was most recently Vice President and Group Executive for Life Sciences. | |||
Mr. Tanda became President and Chief Executive Officer of Aptar in February 2017. Prior to this, Mr. Tanda served from 2007 to 2017 as an Executive Managing Board Director at Royal DSM NV (leading global supplier of ingredients and material solutions for the food, dietary supplement, personal care, medical device, automotive, paint, electronic and bio-material markets), where he was responsible for DSM’s Nutrition and Pharma activities, as well as DSM’s presence in the Americas and various corporate duties. Mr. Tanda is a director of Ingredion Incorporated (a NYSE-listed global supplier of high-quality food and industrial ingredient solutions). Mr. Tanda was a director of Patheon NV (formerly a NYSE-listed company that provided pharmaceutical development and manufacturing services) from March 2016 until the company was sold to Thermo Fisher Scientific in August 2017. | |||
B. CRAIG OWENS Age: 70 Independent Director since: 2018 Committees: Audit (Chair), Management Development and Compensation | |||
Ms. Matthews has been the Chair of Aptar’s Board since May 2023. Ms. Matthews is the former Chief Reputation Officer for Amway Corp. (a company that sells health, beauty and home care products), having served in that role from June 2020 to June 2021, responsible for overseeing Amway’s global reputation strategy and corporate social responsibility. Prior to those roles, Ms. Matthews spent six years as Regional President of the Americas at Amway, heading all operations in North, Central and South America. Prior to joining Amway in 2007 as Chief Marketing Officer, Ms. Matthews served in executive positions at established multinational beauty companies, served as President of the SoftSheen-Carson, Consumer Products Division of L’Oréal USA, held a leadership role at The Coca-Cola Company and an innovation role at CIBA Vision Corporation. She also worked for several other notable companies such as Bausch + Lomb, Procter & Gamble and General Mills. Ms. Matthews currently serves on the board of directors of Société BIC S.A. (a consumer product manufacturer) and Corewell Health Foundation (formerly Spectrum Health Foundation). Ms. Matthews is a former director of MillerKnoll, Inc. (formerly Herman Miller, Inc.) (a modern furniture design company), and Popeye’s Louisiana Kitchen Inc. (a U.S. restaurant chain). | |||
GIOVANNA KAMPOURI MONNAS Age: 69 Independent Director since: 2010 Committees: Management Development and Compensation (Chair) | |||
Ms. Glickman has over 30 years of global financial and operational experience, including in the pharmaceutical industry, and is currently the Chief Financial Officer and Principal Accounting Officer of Criteo S.A., a global commerce media company, since September 2020. She previously held the position of Acting Chief Financial Officer at XPO, Inc., a leading global provider of transportation and logistics solutions, where she previously served as Senior Vice President, Corporate Finance and Transformation. She also held global executive roles at Novartis, Honeywell International and Bristol-Myers Squibb and started her career at PricewaterhouseCoopers. Since 2021, Ms. Glickman has served on the Board of Directors and is Chair of the Audit Committee for 2seventy bio, Inc., a biotech company (previously part of bluebird bio, Inc.) Ms. Glickman joined Aptar’s Board of Directors in 2023. | |||
Mr. Fotiades was the Chairman of the Board of Aptar from May 2018 to May 2023. He has served as Executive Chairman of Elio Health, a private investment firm, since he co-founded the firm in 2022. Mr. Fotiades was the President and CEO of Cantel Medical Corp. (a NYSE-listed manufacturer of infection prevention and control products) from March 2019 until its acquisition by STERIS plc in June 2021. Mr. Fotiades was an Operating Partner in the healthcare practice of Five Arrows Capital Partners (Rothschild Merchant Banking) from April 2017 to March 2019. From 2007 to April 2017, he was a partner of Healthcare Investments at Diamond Castle Holdings LLC (private equity investing). Mr. Fotiades was chairman of Catalent Pharma Solutions, Inc., a provider of advanced technologies for pharmaceutical, biotechnology and consumer health companies, from June 2007 to February 2010. He is currently a director of Prologis, Inc. (a NYSE-listed integrated distribution facilities and services) and previously was a director of Cantel Medical Corp. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Changes in |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonqualified |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non ‐ Equity |
|
Deferred |
|
|
|
|
|
|
|
|
|
|
|
|
Stock |
|
Option |
|
Incentive Plan |
|
Compensation |
|
All Other |
|
|
|
|
|
|
Salary |
|
Bonus |
|
Awards |
|
Awards |
|
Compensation |
|
Earnings |
|
Compensation |
|
Total |
Name and Principal Position |
|
Year |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
Stephan B. Tanda |
|
2024 |
|
1,175,000 |
|
— |
|
5,938,995 |
|
1,631,049 |
|
765,209 |
|
353,814 |
|
63,390 |
|
9,927,457 |
President and |
|
2023 |
|
1,118,500 |
|
168,000 |
|
4,974,288 |
|
1,166,652 |
|
769,829 |
|
658,184 |
|
59,676 |
|
8,915,129 |
Chief Executive Officer |
|
2022 |
|
1,118,500 |
|
— |
|
6,836,783 |
|
— |
|
823,104 |
|
— |
|
62,120 |
|
8,840,507 |
Robert W. Kuhn |
|
2024 |
|
715,364 |
|
— |
|
1,571,635 |
|
381,945 |
|
329,995 |
|
124,047 |
|
15,875 |
|
3,138,861 |
Executive Vice President |
|
2023 |
|
681,299 |
|
72,000 |
|
1,448,503 |
|
302,401 |
|
332,150 |
|
394,194 |
|
16,136 |
|
3,246,683 |
and Chief Financial Officer |
|
2022 |
|
671,174 |
|
— |
|
1,905,883 |
|
— |
|
349,858 |
|
— |
|
26,313 |
|
2,953,228 |
Gael Touya |
|
2024 |
|
601,971 |
|
— |
|
1,132,170 |
|
281,671 |
|
330,140 |
|
226,737 |
|
879,903 |
|
3,452,592 |
President, |
|
2023 |
|
573,294 |
|
54,184 |
|
1,010,498 |
|
220,224 |
|
380,421 |
|
935,699 |
|
765,822 |
|
3,940,142 |
Aptar Pharma |
|
2022 |
|
561,328 |
|
— |
|
1,130,815 |
|
— |
|
503,939 |
|
— |
|
1,089,827 |
|
3,285,909 |
Marc Prieur President, Aptar Beauty |
|
2024 |
|
664,273 |
|
— |
|
964,712 |
|
313,412 |
|
248,547 |
|
139,293 |
|
12,806 |
|
2,343,043 |
|
|
2023 |
|
625,779 |
|
60,217 |
|
817,420 |
|
235,421 |
|
529,491 |
|
126,695 |
|
12,551 |
|
2,407,574 |
|
|
2022 |
|
603,011 |
|
— |
|
1,170,585 |
|
— |
|
734,272 |
|
127,265 |
|
12,094 |
|
2,647,227 |
Hedi Tlili President, Aptar Closures |
|
2024 |
|
575,571 |
|
— |
|
1,028,964 |
|
269,299 |
|
534,080 |
|
389,093 |
|
52,087 |
|
2,849,094 |
Xiangwei Gong |
|
2024 |
|
516,906 |
|
— |
|
743,334 |
|
241,489 |
|
431,221 |
|
92,813 |
|
236,435 |
|
2,262,198 |
Executive Vice President, Strategic Group Development and President, Aptar Asia |
|
2023 |
|
494,647 |
|
46,000 |
|
855,674 |
|
192,111 |
|
235,757 |
|
171,762 |
|
435,987 |
|
2,431,938 |
|
|
2022 |
|
494,647 |
|
— |
|
1,207,463 |
|
— |
|
305,529 |
|
31,247 |
|
358,492 |
|
2,397,378 |
Customers
Customer name | Ticker |
---|---|
Colgate-Palmolive Company | CL |
Performance Food Group Company | PFGC |
Sysco Corporation | SYY |
The Wendy's Company | WEN |
No Suppliers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|---|---|---|
Tanda Stephan B. | - | 204,986 | 3,096 |
Tanda Stephan B. | - | 156,078 | 2,436 |
Kuhn Robert | - | 65,552 | 16,453 |
Touya Gael | - | 33,906 | 0 |
Vinczeller Shiela | - | 27,296 | 0 |
Ackerman Daniel | - | 26,593 | 0 |
Vinczeller Shiela | - | 20,467 | 0 |
Gong Xiangwei | - | 17,859 | 404 |
Prieur Marc | - | 17,745 | 0 |
Prieur Marc | - | 13,828 | 0 |
Gong Xiangwei | - | 10,265 | 555 |
Tlili Hedi | - | 9,379 | 0 |
Tlili Hedi | - | 9,379 | 0 |
Chainey Kimberly | - | 8,619 | 0 |
Chainey Kimberly | - | 7,848 | 0 |
Kampouri Monnas Giovanna | - | 7,582 | 0 |
Matthews Candace S. | - | 6,323 | 0 |
Kanu Vanessa | - | 4,162 | 0 |
Montiel Maritza Gomez | - | 4,024 | 0 |
FOTIADES GEORGE L | - | 3,900 | 0 |
Glickman Sarah JS | - | 894 | 0 |